Intrinsic value of Marrone Bio Innovations - MBII

Previous Close

$1.11

  Intrinsic Value

premium content

  Rating & Target

premium content

  Value-price divergence*

premium content

Previous close

$1.11

 
Intrinsic value premium content
 
Up/down potential premium content
 
Rating premium content
 
Value-price divergence* premium content

Premium access subscription - $499/yr

please register and log in before paying

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of MBII stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.0

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  40.00
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  14
  16
  25
  37
  54
  76
  104
  140
  183
  236
  298
  370
  452
  545
  649
  763
  888
  1,022
  1,167
  1,322
  1,486
  1,660
  1,843
  2,035
  2,236
  2,446
  2,664
  2,892
  3,130
  3,376
  3,632
Variable operating expenses, $m
 
  102
  158
  237
  343
  484
  666
  894
  1,174
  1,510
  1,907
  2,369
  2,896
  3,490
  4,153
  4,883
  5,680
  6,543
  7,470
  8,461
  9,512
  10,624
  11,794
  13,023
  14,309
  15,652
  17,053
  18,511
  20,029
  21,607
  23,247
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  38
  102
  158
  237
  343
  484
  666
  894
  1,174
  1,510
  1,907
  2,369
  2,896
  3,490
  4,153
  4,883
  5,680
  6,543
  7,470
  8,461
  9,512
  10,624
  11,794
  13,023
  14,309
  15,652
  17,053
  18,511
  20,029
  21,607
  23,247
Operating income, $m
  -24
  -86
  -133
  -200
  -290
  -409
  -562
  -754
  -990
  -1,274
  -1,609
  -1,998
  -2,443
  -2,945
  -3,504
  -4,120
  -4,793
  -5,521
  -6,303
  -7,139
  -8,026
  -8,964
  -9,952
  -10,988
  -12,073
  -13,206
  -14,388
  -15,619
  -16,899
  -18,231
  -19,615
EBITDA, $m
  -22
  -83
  -129
  -192
  -279
  -394
  -541
  -726
  -954
  -1,227
  -1,550
  -1,924
  -2,353
  -2,836
  -3,374
  -3,967
  -4,615
  -5,316
  -6,070
  -6,874
  -7,729
  -8,632
  -9,583
  -10,581
  -11,626
  -12,717
  -13,855
  -15,040
  -16,274
  -17,556
  -18,888
Interest expense (income), $m
  6
  3
  3
  5
  8
  11
  16
  23
  31
  41
  52
  66
  83
  101
  122
  145
  171
  199
  229
  262
  297
  334
  373
  414
  457
  502
  550
  599
  650
  703
  759
Earnings before tax, $m
  -31
  -89
  -136
  -204
  -297
  -420
  -578
  -777
  -1,021
  -1,315
  -1,662
  -2,065
  -2,526
  -3,046
  -3,626
  -4,265
  -4,964
  -5,720
  -6,532
  -7,401
  -8,323
  -9,298
  -10,324
  -11,402
  -12,530
  -13,709
  -14,938
  -16,218
  -17,549
  -18,934
  -20,374
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -31
  -89
  -136
  -204
  -297
  -420
  -578
  -777
  -1,021
  -1,315
  -1,662
  -2,065
  -2,526
  -3,046
  -3,626
  -4,265
  -4,964
  -5,720
  -6,532
  -7,401
  -8,323
  -9,298
  -10,324
  -11,402
  -12,530
  -13,709
  -14,938
  -16,218
  -17,549
  -18,934
  -20,374

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  10
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  46
  82
  126
  189
  274
  386
  531
  713
  936
  1,204
  1,521
  1,888
  2,308
  2,783
  3,311
  3,893
  4,528
  5,216
  5,955
  6,745
  7,583
  8,469
  9,402
  10,382
  11,407
  12,478
  13,594
  14,757
  15,967
  17,225
  18,532
Adjusted assets (=assets-cash), $m
  36
  82
  126
  189
  274
  386
  531
  713
  936
  1,204
  1,521
  1,888
  2,308
  2,783
  3,311
  3,893
  4,528
  5,216
  5,955
  6,745
  7,583
  8,469
  9,402
  10,382
  11,407
  12,478
  13,594
  14,757
  15,967
  17,225
  18,532
Revenue / Adjusted assets
  0.389
  0.195
  0.198
  0.196
  0.197
  0.197
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
  0.196
Average production assets, $m
  19
  16
  25
  37
  54
  76
  104
  140
  183
  236
  298
  370
  452
  545
  649
  763
  888
  1,022
  1,167
  1,322
  1,486
  1,660
  1,843
  2,035
  2,236
  2,446
  2,664
  2,892
  3,130
  3,376
  3,632
Working capital, $m
  12
  6
  10
  15
  21
  30
  42
  56
  73
  94
  119
  148
  181
  218
  260
  305
  355
  409
  467
  529
  595
  664
  737
  814
  894
  978
  1,066
  1,157
  1,252
  1,350
  1,453
Total debt, $m
  59
  58
  99
  155
  231
  333
  463
  626
  827
  1,068
  1,354
  1,684
  2,063
  2,489
  2,965
  3,488
  4,060
  4,679
  5,345
  6,055
  6,810
  7,607
  8,447
  9,329
  10,251
  11,215
  12,220
  13,266
  14,355
  15,487
  16,664
Total liabilities, $m
  76
  73
  114
  170
  246
  348
  478
  641
  842
  1,083
  1,369
  1,699
  2,078
  2,504
  2,980
  3,503
  4,075
  4,694
  5,360
  6,070
  6,825
  7,622
  8,462
  9,344
  10,266
  11,230
  12,235
  13,281
  14,370
  15,502
  16,679
Total equity, $m
  -30
  8
  13
  19
  27
  39
  53
  71
  94
  120
  152
  189
  231
  278
  331
  389
  453
  522
  596
  674
  758
  847
  940
  1,038
  1,141
  1,248
  1,359
  1,476
  1,597
  1,722
  1,853
Total liabilities and equity, $m
  46
  81
  127
  189
  273
  387
  531
  712
  936
  1,203
  1,521
  1,888
  2,309
  2,782
  3,311
  3,892
  4,528
  5,216
  5,956
  6,744
  7,583
  8,469
  9,402
  10,382
  11,407
  12,478
  13,594
  14,757
  15,967
  17,224
  18,532
Debt-to-equity ratio
  -1.967
  7.160
  7.810
  8.200
  8.450
  8.610
  8.720
  8.790
  8.840
  8.880
  8.900
  8.920
  8.940
  8.950
  8.950
  8.960
  8.970
  8.970
  8.970
  8.980
  8.980
  8.980
  8.980
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
  8.990
Adjusted equity ratio
  -1.111
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -31
  -89
  -136
  -204
  -297
  -420
  -578
  -777
  -1,021
  -1,315
  -1,662
  -2,065
  -2,526
  -3,046
  -3,626
  -4,265
  -4,964
  -5,720
  -6,532
  -7,401
  -8,323
  -9,298
  -10,324
  -11,402
  -12,530
  -13,709
  -14,938
  -16,218
  -17,549
  -18,934
  -20,374
Depreciation, amort., depletion, $m
  2
  3
  5
  7
  11
  15
  21
  28
  37
  47
  60
  74
  90
  109
  130
  153
  178
  204
  233
  264
  297
  332
  369
  407
  447
  489
  533
  578
  626
  675
  726
Funds from operations, $m
  -24
  -86
  -131
  -197
  -287
  -405
  -557
  -749
  -984
  -1,267
  -1,602
  -1,991
  -2,435
  -2,937
  -3,496
  -4,113
  -4,786
  -5,515
  -6,299
  -7,136
  -8,025
  -8,966
  -9,956
  -10,995
  -12,083
  -13,220
  -14,405
  -15,639
  -16,924
  -18,259
  -19,647
Change in working capital, $m
  0
  2
  3
  5
  7
  9
  11
  14
  17
  21
  25
  29
  33
  37
  41
  46
  50
  54
  58
  62
  66
  69
  73
  77
  80
  84
  88
  91
  95
  99
  103
Cash from operations, $m
  -24
  -98
  -135
  -202
  -293
  -414
  -569
  -763
  -1,002
  -1,289
  -1,627
  -2,020
  -2,468
  -2,974
  -3,538
  -4,158
  -4,836
  -5,569
  -6,357
  -7,198
  -8,091
  -9,035
  -10,029
  -11,072
  -12,163
  -13,304
  -14,492
  -15,730
  -17,018
  -18,358
  -19,750
Maintenance CAPEX, $m
  0
  -2
  -3
  -5
  -7
  -11
  -15
  -21
  -28
  -37
  -47
  -60
  -74
  -90
  -109
  -130
  -153
  -178
  -204
  -233
  -264
  -297
  -332
  -369
  -407
  -447
  -489
  -533
  -578
  -626
  -675
New CAPEX, $m
  0
  -6
  -9
  -12
  -17
  -22
  -28
  -36
  -44
  -53
  -62
  -72
  -82
  -93
  -104
  -114
  -125
  -135
  -145
  -155
  -164
  -174
  -183
  -192
  -201
  -210
  -219
  -228
  -237
  -247
  -256
Cash from investing activities, $m
  0
  -8
  -12
  -17
  -24
  -33
  -43
  -57
  -72
  -90
  -109
  -132
  -156
  -183
  -213
  -244
  -278
  -313
  -349
  -388
  -428
  -471
  -515
  -561
  -608
  -657
  -708
  -761
  -815
  -873
  -931
Free cash flow, $m
  -24
  -106
  -147
  -219
  -317
  -446
  -612
  -820
  -1,073
  -1,378
  -1,736
  -2,151
  -2,625
  -3,158
  -3,750
  -4,402
  -5,113
  -5,881
  -6,706
  -7,586
  -8,520
  -9,506
  -10,544
  -11,632
  -12,771
  -13,961
  -15,200
  -16,491
  -17,834
  -19,230
  -20,681
Issuance/(repayment) of debt, $m
  -1
  1
  40
  56
  77
  101
  130
  164
  201
  241
  285
  331
  378
  427
  475
  524
  572
  619
  665
  710
  755
  798
  840
  881
  923
  964
  1,005
  1,047
  1,089
  1,132
  1,177
Issuance/(repurchase) of shares, $m
  0
  115
  111
  169
  249
  356
  496
  674
  895
  1,163
  1,483
  1,857
  2,288
  2,778
  3,328
  3,937
  4,605
  5,331
  6,115
  6,955
  7,849
  8,797
  9,797
  10,849
  11,951
  13,104
  14,307
  15,561
  16,866
  18,224
  19,635
Cash from financing (excl. dividends), $m  
  14
  116
  151
  225
  326
  457
  626
  838
  1,096
  1,404
  1,768
  2,188
  2,666
  3,205
  3,803
  4,461
  5,177
  5,950
  6,780
  7,665
  8,604
  9,595
  10,637
  11,730
  12,874
  14,068
  15,312
  16,608
  17,955
  19,356
  20,812
Total cash flow (excl. dividends), $m
  -10
  -105
  -107
  -163
  -241
  -345
  -482
  -656
  -873
  -1,136
  -1,451
  -1,820
  -2,246
  -2,731
  -3,275
  -3,878
  -4,541
  -5,262
  -6,041
  -6,876
  -7,765
  -8,708
  -9,704
  -10,751
  -11,849
  -12,997
  -14,195
  -15,445
  -16,745
  -18,098
  -19,504
Retained Cash Flow (-), $m
  28
  -29
  -4
  -6
  -9
  -11
  -14
  -18
  -22
  -27
  -32
  -37
  -42
  -47
  -53
  -58
  -64
  -69
  -74
  -79
  -84
  -89
  -93
  -98
  -103
  -107
  -112
  -116
  -121
  -126
  -131
Prev. year cash balance distribution, $m
 
  19
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Discount rate, %
 
  11.80
  12.39
  13.01
  13.66
  14.34
  15.06
  15.81
  16.60
  17.43
  18.31
  19.22
  20.18
  21.19
  22.25
  23.36
  24.53
  25.76
  27.05
  28.40
  29.82
  31.31
  32.87
  34.52
  36.24
  38.06
  39.96
  41.96
  44.05
  46.26
  48.57
PV of cash for distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  100
  50.0
  3.4
  0.2
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Marrone Bio Innovations, Inc. provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation. The company’s products include Regalia, a plant extract-based fungicidal biopesticide for plant disease control and plant health; and Grandevo, a bioinsecticide for insect and mite control to the growers of specialty crops, such as grapes, citrus, tomatoes, vegetables, nuts, leafy greens, and ornamental plants. It also provides Zequanox, a biomolluscicide that kills invasive mussels, which cause infrastructure and ecological damage primarily to power and industrial companies; and Venerate, a bioinsecticide, which kills a range of chewing and sucking insects and mites, as well as flies and plant parasitic nematodes. In addition, the company offers Majestene, a bionematicide to control soil-dwelling nematodes by preventing and reducing root galls, as well as reducing adult reproduction and egg hatch. Marrone Bio Innovations, Inc. provides its products directly, as well as through distributors. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was founded in 2006 and is headquartered in Davis, California.

FINANCIAL RATIOS  of  Marrone Bio Innovations (MBII)

Valuation Ratios
P/E Ratio -0.9
Price to Sales 2
Price to Book -0.9
Price to Tangible Book
Price to Cash Flow -1.1
Price to Free Cash Flow -1.1
Growth Rates
Sales Growth Rate 40%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -100%
Cap. Spend. - 3 Yr. Gr. Rate -100%
Financial Strength
Quick Ratio 10
Current Ratio 0.3
LT Debt to Equity -193.3%
Total Debt to Equity -196.7%
Interest Coverage -4
Management Effectiveness
Return On Assets -42.7%
Ret/ On Assets - 3 Yr. Avg. -55.8%
Return On Total Capital -72.9%
Ret/ On T. Cap. - 3 Yr. Avg. -81.5%
Return On Equity 193.8%
Return On Equity - 3 Yr. Avg. -78.2%
Asset Turnover 0.2
Profitability Ratios
Gross Margin 35.7%
Gross Margin - 3 Yr. Avg. 15.2%
EBITDA Margin -164.3%
EBITDA Margin - 3 Yr. Avg. -355.5%
Operating Margin -171.4%
Oper. Margin - 3 Yr. Avg. -368.6%
Pre-Tax Margin -221.4%
Pre-Tax Margin - 3 Yr. Avg. -413.1%
Net Profit Margin -221.4%
Net Profit Margin - 3 Yr. Avg. -413.1%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

MBII stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MBII stock intrinsic value calculation we used $10 million for the last fiscal year's total revenue generated by Marrone Bio Innovations. The default revenue input number comes from 2016 income statement of Marrone Bio Innovations. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MBII stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 11.8%, whose default value for MBII is calculated based on our internal credit rating of Marrone Bio Innovations, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Marrone Bio Innovations.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MBII stock the variable cost ratio is equal to 640%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for MBII stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 4.9% for Marrone Bio Innovations.

Corporate tax rate of 27% is the nominal tax rate for Marrone Bio Innovations. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MBII stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MBII are equal to 100%.

Life of production assets of 2.5 years is the average useful life of capital assets used in Marrone Bio Innovations operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MBII is equal to 40%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-2 million for Marrone Bio Innovations - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 23.463 million for Marrone Bio Innovations is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Marrone Bio Innovations at the current share price and the inputted number of shares is $0.0 billion.


Premium access subscription - $499/yr

please register and log in before paying
RELATED COMPANIES Price Int.Val. Rating
FMC FMC 74.26 prem.  prem.
SYT Syngenta ADR 92.60 prem.  prem.
AVD American Vangu 17.65 prem.  prem.
SMG Scotts Miracle 88.33 prem.  prem.
MON Monsanto 116.84 prem.  prem.
DD E.I. DuPont de 81.34 prem.  prem.

COMPANY NEWS

▶ 5 things to know, and photos from Mikuni's big anniversary party   [May-10-17 11:31AM  American City Business Journals]
▶ Marrone Bio Innovations Hosts Grower Nematicide Training   [Feb-21-17 10:00AM  GlobeNewswire]
▶ Marrone Bio Innovations to Hold Bioinsecticides Webinar   [Feb-10-17 06:00AM  GlobeNewswire]
▶ Ed Goldman: Pam Marrone has declared war on weeds   [Oct-06-16 05:28PM  at bizjournals.com]
▶ Ed Goldman: Pam Marrones rollercoaster ride is smoothing out   [Oct-05-16 11:40AM  at bizjournals.com]
▶ Marrone Bio posts smaller loss, growing sales   [May-12-16 07:07PM  at bizjournals.com]
Stock chart of MBII Financial statements of MBII Annual reports of MBII
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.